Sprycel — Total Revenues
Bristol-Myers Squibb Sprycel — Total Revenues decreased by 8.8% to $73M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 58.3%, from $175M to $73M. Over 4 years (FY 2021 to FY 2025), Sprycel — Total Revenues shows a downward trend with a -30.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand and successful patient retention, while a decrease may signal increased competition from generics or a shift in clinical treatment standards.
Detailed definition
This metric represents the total global net sales generated from the pharmaceutical product Sprycel, a tyrosine kinase i...
Peer comparison
Similar to revenue metrics for mature, branded oncology assets at other large-cap pharmaceutical companies, where performance is often evaluated based on patent expiration timelines and market share retention.
bmy_segment_sprycel_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $541M | $551M | $555M | $483M | $544M | $560M | $578M | $429M | $458M | $517M | $526M | $374M | $424M | $290M | $198M | $175M | $120M | $119M | $80M | $73M |
| QoQ Change | — | +1.8% | +0.7% | -13.0% | +12.6% | +2.9% | +3.2% | -25.8% | +6.8% | +12.9% | +1.7% | -28.9% | +13.4% | -31.6% | -31.7% | -11.6% | -31.4% | -0.8% | -32.8% | -8.8% |
| YoY Change | — | — | — | — | +0.6% | +1.6% | +4.1% | -11.2% | -15.8% | -7.7% | -9.0% | -12.8% | -7.4% | -43.9% | -62.4% | -53.2% | -71.7% | -59.0% | -59.6% | -58.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's sprycel — total revenues?
- Bristol-Myers Squibb (BMY) reported sprycel — total revenues of $73M in Q1 2026.
- How has Bristol-Myers Squibb's sprycel — total revenues changed year-over-year?
- Bristol-Myers Squibb's sprycel — total revenues decreased by 58.3% year-over-year, from $175M to $73M.
- What is the long-term trend for Bristol-Myers Squibb's sprycel — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's sprycel — total revenues has grown at a -30.5% compound annual growth rate (CAGR), from $2.12B to $494M.
- What does sprycel — total revenues mean?
- The total revenue generated from sales of the oncology drug Sprycel.